Back

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Pro.

8 November 2019 (14:50 - 15:00)
Organised by:
Congress Presentation Part of: Controversies in 2019 Valvular Heart Disease ESC Premium Access ESC Asia with APSC & AFC

About the speaker

Photo
Professor Mohamed Marwan

Friedrich Alexander University Erlangen Nuernberg, Erlangen (Germany)

5 More presentations in this session

Presentation thumbnail
Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure - Pro.
Associate Professor D. Sim (Singapore, SG)
Slides Video
Presentation thumbnail
Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure- Contra.
Professor J. Cleland (Glasgow, GB)
Slides Video
Presentation thumbnail
Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure concluding discussion.
Presentation thumbnail
PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Contra
Associate Professor K. Sin (Singapore, SG)
Slides Video
Presentation thumbnail
PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Concluding discussion.
Video

Access the full session

Session thumbnail
Controversies in 2019

The Event

Event poster

ESC Asia with APSC & AFC

8 November 2019 14:50 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources